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With an estimated 5.6 million people living with HIV in 2011, South 
Africa (SA)’s epidemic remains the largest in the world.[1] SA is also 
the country with the third-highest tuberculosis (TB) burden globally, 
and is only lagging behind countries such as China and India that 
have significantly larger populations.[2] 
TB is also the most common cause of morbidity and mortality in 
the HIV-infected population in SA, and studies have shown that TB 
accelerates the progression of HIV/AIDS.[3] 
Since 1993, when the World Health Organization (WHO) declared 
TB a global public health emergency because of 7 - 8 million recor-
ded cases, the spread of TB increased to about 9 million new cases in 
2011. [4] TB is the second leading cause of death from an infectious 
disease worldwide after HIV, and accounted for an estimated 1.4 mil-
lion deaths in 2011.[4] This includes an estimated 430 000 deaths from 
TB among people living with HIV (PLHIV).[4] 
HIV is the strongest risk factor recognised so far in reactivating 
latent Mycobacterium tuberculosis infection to active TB disease, or 
increasing susceptibility to new infection.[5] The risk of active TB 
increases soon after HIV seroconversion and doubles by the end of 
the first year of HIV infection.[6] 
Isoniazid preventive therapy (IPT) is one of the interventions 
that the World Health Organization (WHO) and the SA National 
Department of Health (NDoH) recommend to prevent progression 
to active TB disease in PLHIV. The WHO, with a high quality of 
evidence, strongly recommends that these individuals receive IPT 
irrespective of their degree of immunosuppression.
The protective effect of TB preventive therapy is expected to last for 
approximately 18 months, so the therapy should be given once during 
this period.[4] The lifetime risk of an infected but immunocompetent 
individual developing active TB disease is around 10%, with the 
highest risk in the first 2 years following infection. [7] The risk 
increases to around 10% per year in an individual living with HIV.[8]
In addition to high rates of reactivation TB, HIV-infected indi-
viduals have increased susceptibility to new exogenous infection and 
rapidly progressive primary disease. HIV-positive individuals who 
are co-infected with TB are about 21 - 24 times more likely to develop 
active TB disease than those who are HIV-negative.[5]
From a public health perspective, IPT is cost-effective, extends 
life expectancy, reduces the incidence of TB, and promotes savings 
in medical and social costs for adults with HIV, especially those who 
are tuberculin skin test (TST)-positive.[5] While individuals who are 
eligible for antiretroviral therapy (ART) should start it, all PLHIV in 
whom active TB has been excluded should be started on IPT, with the 
exception of those who abuse alcohol or have an increased likelihood 
of side-effects, in which case the NDoH states that counselling should 
precede IPT.
Notwithstanding the absence of definitive evidence from 
randomised controlled trials on the optimal duration of IPT in 
HIV-infected patients, data from several observational studies 
demonstrate that IPT is cost-effective and beneficial because it 
combats low bacillary load latent TB, which serves as a reservoir for 
recurrent disease.
Methods
A quantitative non-experimental descriptive retrospective cohort 
study was performed in a clinic in an industrial area adjacent to a 
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Results. Sixty-six of 104 study respondents (63.5%) completed the IPT course. None of the respondents who completed IPT was diagnosed 
with TB, and 86.8% of the respondents who did not complete the programme did so because of the poor quality of healthcare they received, 
and not by their own choice.
Conclusion. The study results strengthened the findings of similar local and international studies that IPT is advantageous in the prevention 
of TB. The finding that so many patients did not complete the programme as a result of drug dispensing or prescription problems is 
alarming, and revealed a major shortcoming in the healthcare system.
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formal urban settlement in the iLembe Health District, KwaZulu-
Natal Province (KZN), SA. The clinic provides the full complement of 
HIV/AIDS/TB management to the inhabitants of the area.
Using a consecutive sampling method, the researchers collected 
data between July 2010 and November 2011. They used the daily 
clinic attendance register to obtain 441 applicable records for the 
study, and 104 HIV-infected adult clients met the eligibility criteria 
and formed the sample. The criteria for inclusion were evidence 
that the patient tested HIV-positive, was >18 years of age and had 
commenced IPT. The cut-off enrolment month of November 2011 
applied because the researchers followed the records of the patients 
for 15 - 30 months to ascertain whether they developed active TB 
disease after using IPT. They screened the files of all the subjects for 
TB prior to commencing intake of IPT. Twelve subjects also had their 
sputum tested for acid-fast bacilli before starting ART. The sputum 
testing was done because they answered in the affirmative to at 
least one of the questions in the screening tool and were diagnosed 
with TB prior to IPT treatment. The researchers also developed a 
data-capturing instrument based on the objectives of the study and 
pretested it to gather the required data.
Ethical considerations
Ethical approval was obtained from the research ethics committee of 
the University of South Africa (ref. no. HSHDC/92/2012), the Dep-
artment of Health (KZN) (ref. no. HRKM 011/13) and the iLembe 
Health District (ref. no. DM2012/09/2289). In order to maintain 
anonymity and confidentiality, the files were coded but names and 
file numbers were not entered.
Statistical analysis
Data were analysed using the SPSS statistical software program, 
version 21 (IBM, USA). Descriptive statistics were used to describe 
the demographic characteristics, and analytical statistics using 
the χ2  test to measure the associations between gender and age 
distributions of the subjects and those who completed IPT at 6 and 
9  months. The 95% level of confidence (95% confidence interval) 
and a probability of p<0.05 were used as the definition of significance 
while comparing the groups.
Results
One hundred and four clinic records of HIV-positive adults receiving 
care at a clinic and meeting the inclusion criteria were abstracted for 
analysis. Of these, 63.5% (n=66) were female and 36.5% (n=38) male 
(Table 1). There was no statistical significance between female and 
male respondents who completed IPT at 9 months (p=2.699).
Of the subjects, 31.7% (n=33) completed IPT within 6 months 
and 63.5% (n=66) within 9 months. Some could not collect their 
medication because of the unavailability of isoniazid; however, they 
did complete IPT within 9 months.
The reasons for 36.5% of subjects (n=38) not completing the IPT 
course were identified as unavailability of drugs (18.4%, n=7), loss 
to follow-up (13.2%, n=5) and, most importantly, 68.4% (n=26) to 
whom IPT was not prescribed (Fig. 1). The clinical records of the 
affected patients did not state the exact reasons for this.
None of the 66 respondents who completed IPT at the end of 
9 months was diagnosed with TB at the conclusion of data gathering. 
The study findings confirmed the results of other studies that IPT 
for at least 6 months or up to 9 months was successful in preventing 
TB. Incidence rates of 0.80 per 100 person-years[9] and 2.3 per 
100 person-years[10] have been reported elsewhere.
Only 5 (13.2%) of the subjects who did not complete IPT were 
responsible for not doing so. The other 33 (86.5%) did not complete 
IPT because isoniazid was either not prescribed or out of stock.
Discussion
It is a cause for concern that IPT was either not prescribed or 
unavailable in so many cases, since the study results confirm the 
findings of other studies that IPT for at least 6 months and up to 
9 months successfully prevented TB.
To ensure quality healthcare, the required drugs must be available. 
The current national treatment guidelines in SA[11] recommend 
the use of a TST before commencing IPT. This practice should be 
standardised to ensure that the appropriate duration of IPT can be 
adhered to in order to implement research evidence, thus promoting 
evidence-based practice in healthcare delivery. Healthcare workers 
need to take responsibility for the quality of the healthcare they 
deliver, including the procurement of drugs to ensure the availability 
of IPT.
Performance appraisal should include aspects such as timely 
ordering of medication, accountability for negligence to order 
medi cation, and attending workshops and continuing professional 
development sessions. Healthcare professionals who do not meet 
their responsibilities in providing quality healthcare as stipulated in 
their job descriptions should be held accountable for poor quality of 
healthcare, and the necessary actions should be taken against them.
It was evident that IPT for at least 6 months successfully prevented 
TB. It therefore remains a serious concern that inadequate healthcare 
or possible incompetence of healthcare providers were the main 
reasons for patients not completing IPT despite positive evidence of 
its effectiveness. It is, however, important to note that the study was 
conducted in the catchment area of one clinic in one health district, 
and cannot be generalised to other contexts.
Author contributions. EIO conducted the research, wrote the initial 
reports and funded the study. LR contributed to writing the proposal, 
Table 1. Gender distribution of subjects who completed IPT at 9 months
Completed at 9 months Females, n (%) Males, n (%) Total, n (%)
Yes 28 (42.4) 10 (26.3) 38 (36.5)
No 38 (57.6) 28 (73.7) 66 (63.5)
Total 66 (100.0) 38 (100.0) 104 (100.0)
7 (18.4%)
Drug not prescribed




Fig. 1. Reasons for not completing IPT (N=38).
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research design and instrument development, data interpretation and 
writing the report.
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